Skip to main content Accessibility help
×
Home

The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study

  • Howard Chertkow (a1) (a2), Michael Borrie (a3) (a4), Victor Whitehead (a2), Sandra E. Black (a5) (a6), Howard H. Feldman (a7) (a8) (a9), Serge Gauthier (a10) (a11), David B. Hogan (a12) (a9), Mario Masellis (a5) (a6), Katherine McGilton (a13) (a14), Kenneth Rockwood (a15), Mary C. Tierney (a6) (a16), Melissa Andrew (a1) (a2) (a5) (a6) (a3) (a4) (a7) (a8) (a10) (a12) (a9) (a13) (a14) (a15) (a17) (a18) (a16) (a19) (a20) (a21) (a22) (a23) (a24) (a25) (a26) (a27) (a28) (a29) (a30) (a31) (a11), Ging-Yuek R. Hsiung (a7) (a19), Richard Camicioli (a20) (a21), Eric E. Smith (a9) (a22), Jennifer Fogarty (a4) (a23), Joseph Lindsay (a4), Sarah Best (a1) (a2) (a5) (a6) (a3) (a4) (a7) (a8) (a10) (a12) (a9) (a13) (a14) (a15) (a17) (a18) (a16) (a19) (a20) (a21) (a22) (a23) (a24) (a25) (a26) (a27) (a28) (a29) (a30) (a31) (a11), Alan Evans (a24), Samir Das (a25), Zia Mohaddes (a25), Randi Pilon (a2), Judes Poirier (a10), Natalie A. Phillips (a26), Elizabeth MacNamara (a27), Roger A. Dixon (a28), Simon Duchesne (a29) (a30), Ian MacKenzie (a31) and R. Jane Rylett (a14) (a15) (a17) (a18)...

Abstract:

Background:

The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) cohort study of the Canadian Consortium on Neurodegeneration in Aging (CCNA) is a national initiative to catalyze research on dementia, set up to support the research agendas of CCNA teams. This cross-country longitudinal cohort of 2310 deeply phenotyped subjects with various forms of dementia and mild memory loss or concerns, along with cognitively intact elderly subjects, will test hypotheses generated by these teams.

Methods:

The COMPASS-ND protocol, initial grant proposal for funding, fifth semi-annual CCNA Progress Report submitted to the Canadian Institutes of Health Research December 2017, and other documents supplemented by modifications made and lessons learned after implementation were used by the authors to create the description of the study provided here.

Results:

The CCNA COMPASS-ND cohort includes participants from across Canada with various cognitive conditions associated with or at risk of neurodegenerative diseases. They will undergo a wide range of experimental, clinical, imaging, and genetic investigation to specifically address the causes, diagnosis, treatment, and prevention of these conditions in the aging population. Data derived from clinical and cognitive assessments, biospecimens, brain imaging, genetics, and brain donations will be used to test hypotheses generated by CCNA research teams and other Canadian researchers. The study is the most comprehensive and ambitious Canadian study of dementia. Initial data posting occurred in 2018, with the full cohort to be accrued by 2020.

Conclusion:

Availability of data from the COMPASS-ND study will provide a major stimulus for dementia research in Canada in the coming years.

Évaluation complète d’une étude de cohorte canadienne portant sur la démence et la neuro-dégénérescence. Contexte : L’évaluation globale de la neuro-dégénérescence et de la démence (COMPASS-ND), étude de cohorte du Consortium canadien en neuro-dégénérescence associée au vieillissement (CCNV), représente une initiative nationale visant à promouvoir la recherche portant sur la démence et à soutenir les programmes de recherche des équipes du CCNV. Totalisant 2310 sujets recrutés partout au pays, cette cohorte longitudinale regroupe des individus fortement « phénotypés » qui présentent diverses formes de démence et de pertes de mémoire légères. En plus de sujets âgés dont les fonctions cognitives sont intactes, ces 2310 sujets ont permis de valider les hypothèses formulées par les équipes du CCNV. Méthodes : Nous avons utilisé de nombreux documents pour décrire cette étude : le protocole de la COMPASS-ND ; la demande initiale de subvention ; le cinquième rapport d’étape semi-annuel du CCNV soumis aux Instituts de recherche en santé du Canada (IRSC) en décembre 2017 ; ainsi que d’autres documents produits à la suite de modifications consécutives à la mise en œuvre de ce projet. Résultats: L’étude de cohorte COMPASS-ND du CCNV inclut des participants de partout au Canada dont les divers états cognitifs sont associés à des maladies neurodégénératives ou au risque d’en souffrir. Ils feront l’objet d’un large éventail d’examens expérimentaux, cliniques, génétiques et d’imagerie afin d’aborder de manière spécifique les causes, le diagnostic, le traitement et la prévention de ces états cognitifs chez les personnes âgées. Les données obtenues à la suite d’évaluations cliniques et cognitives, ainsi que celles issues d’échantillons biologiques, d’imagerie cérébrale, de tests génétiques et de dons de cerveaux, seront utilisées pour tester les hypothèses générées par les équipes de recherche du CCNV et d’autres chercheurs canadiens. Cette étude constitue donc à ce jour l’étude canadienne la plus complète et la plus ambitieuse au sujet de la démence. La présentation des données initiales ayant eu lieu en 2018, la cohorte devrait atteindre sa taille maximale d’ici à 2020.Conclusion : La disponibilité des données de l’étude COMPASS-ND stimulera considérablement la recherche sur la démence au Canada au cours des prochaines années.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

Correspondence to: Howard Chertkow, Kimel Family Building, Baycrest Health Sciences, 3560 Bathurst Street, Toronto, Ontario, M6A 2E1, Canada. Email: Howard.chertkow@mcgill.ca

References

Hide All
1. Alzheimer Society of Canada. Rising tide: the impact of dementia on Canadian society. Toronto: Alzheimer Society of Canada; 2010.
2. Gorelick, PB, Scuteri, A, Black, SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672–713.
3. Iadecola, C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844–66.
4. Schneider, JA, Boyle, PA, Arvanitakis, Z, Bienias, JL, Bennett, DA. Subcortical infarcts, Alzheimer’s disease pathology, and memory function in older persons. Ann Neurol. 2007;62(1):5966.
5. Snowden, JS, Neary, D, Mann, DM. Frontotemporal dementia. Br J Psychiatry. 2002;180:140–3.
6. Kertesz, A. Frontotemporal dementia/Pick’s disease. Arch Neurol. 2004;61(6):969–71.
7. Hogan, DB, Fiest, KM, Roberts, JI, et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S83–95.
8. Petersen, RC, Negash, S. Mild cognitive impairment: an overview. CNS Spectr. 2008;13(1):4553.
9. Morris, JC, Mild cognitive impairment is early-stage Alzheimer disease. Arch Neurol. 2006;63:1516.
10. Sachdev, PS, Lipnicki, DM, Crawford, J, et al. Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study. PLoS One. 2013;8(3):e59649.
11. Reisberg, B, Gauthier, S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer’s disease. Int Psychogeriatr. 2008;20(1):116.
12. Jessen, F, Wolfsgruber, S, Wiese, B, et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement. 2014;10(1):7683.
13. Das, S, Zijdenbos, AP, Harlap, J, Vins, D, Evans, AC. LORIS: a web-based data management system for multi-center studies. Front Neuroinform. 2011;5:37.
14. Raina, PS, Wolfson, C, Kirkland, SA, et al. The Canadian longitudinal study on aging (CLSA). Can J Aging. 2009;28(3):221–9.
15. Weiner, MW, Veitch, DP, Aisen, PS, et al. Impact of the Alzheimer’s disease neuroimaging initiative, 2004 to 2014. Alzheimers Dement. 2015;11(7):865–84.
16. Shatenstein, B, Nadon, S, Godin, C, Ferland, G. Development and validation of a food frequency questionnaire. Can J Diet Pract Res. 2005;66(2):6775.
17. Montero-Odasso, M, Pieruccini-Faria, F, Bartha, R, et al. Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). J Alzheimers Dis. 2017;59(2): 707–21.
18. Schneider, JA, Arvanitakis, Z, Leurgans, SE, Bennett, DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200–8.
19. Iturria-Medina, Y, Hachinski, V, Evans, AC. The vascular facet of late-onset Alzheimer’s disease: an essential factor in a complex multifactorial disorder. Curr Opin Neurol. 2017;30(6):623–9.
20. Smith, EE, Beaudin, AE. New insights into cerebral small vessel disease and vascular cognitive impairment from MRI. Curr Opin Neurol. 2018;31(1):3643.
21. Nestor, SM, Misic, B, Ramirez, J, et al. Small vessel disease is linked to disrupted structural network covariance in Alzheimer’s disease. Alzheimers Dement. 2017;13(7):749–60.
22. Marian, V, Blumenfeld, HK, Kaushanskaya, M, The Language Experience and Proficiency Questionnaire (LEAP-Q): assessing language profiles in bilinguals and multilinguals. J Speech Lang Hear Res. 2007;50(4):940–67.
23. Wechsler, D. Wechsler memory scale - revised. San Antonio: The Psychological Corporation; 1987.
24. Morris, JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.
25. Welsh, KA, Butters, N, Mohs, RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994;44(4):609–14.
26. Nasreddine, ZS, Phillips, NA, Bedirian, V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.
27. Lawton, M, Brody, EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179196.
28. Possin, KL, Laluz, VR, Alcantar, OZ, Miller, BL, Kramer, JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer’s disease and behavioral variant frontotemporal dementia. Neuropsychologia. 2011; 49(1):43–8.
29. Folstein, MF, Folstein, SE, McHugh, PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
30. FTLD Working Group of the ADC program. NACC Uniform Data Set (UDS)-FTLD Module Version 3.0. Seattle, WA: University of Washington; 2015.
31. Cummings, JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–6.
32. Jenkinson, C, Fitzpatrick, R, Peto, V, Greenhall, R, Hyman, N. The Parkinson’s disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26(5):353–7.
33. Goetz, CG, Fahn, S, Martinez-Martin, P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41–7.
34. Hachinski, VC, Iliff, LD, Zilhka, E, Cerebral blood flow in dementia. Arch Neurol. 1975;32(9):632–7.
35. Belleville, S, Fouquet, C, Duchesne, S, Collins, DL, Hudon, C. Detecting early preclinical Alzheimer’s disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing. J Alzheimers Dis. 2014;42:S375–82.
36. Stuss, DT. The Ontario Brain Institute: completing the circle. Can J Neurol Sci. 2014;41(6):683–93.
37. Hallam, BJ, Jacova, C, Hsiung, GY, et al. Early neuropsychological characteristics of progranulin mutation carriers. J Int Neuropsychol Soc. 2014;20(7):694703.
38. de Frias, CM, Dixon, RA, Camicioli, R. Neurocognitive speed and inconsistency in Parkinson’s disease with and without incipient dementia: an 18-month prospective cohort study. J Int Neuropsychol Soc. 2012;18(4):764–72.
39. O’Bryant, SE, Xiao, G, Barber, R, et al. A blood-based screening tool for Alzheimer’s disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011;6(12):e28092.
40. Agarwal, R, Tripathi, CB. Diagnostic utility of CSF Tau and Abeta(42) in dementia: a meta-analysis. Int J Alzheimers Dis. 2011;2011:503293.
41. Pekeles, H, Qureshi, HY, et al. Development and validation of a salivary tau biomarker in Alzheimer disease. Alzheimers Dement. 2019;11:5360.
42. Vellas, B, Hampel, H, Rougé-Bugat, ME, et al. Alzheimer’s disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging. 2012;16(4):339–45.
43. Duchesne, S, Valdivia, F, Robitaille, N et al. Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. Alzheimers Dement. 2015;11(2):161–74.
44. Anandh, KR, Sujatha, CM, Ramakrishnan, S. A method to differentiate mild cognitive impairment and Alzheimer in MR images using Eigen value descriptors. J Med Syst. 2016;40(1):25.
45. Wardlaw, JM, Smith, EE, Biessels, GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.
46. Fazekas, F, Kleinert, R, Offenbacher, H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683–9.
47. Hardy, J, Orr, H. The genetics of neurodegenerative diseases. J Neurochem. 2006;97(6):1690–9.
48. Caracciolo, B, Xu, W, Collins, S, Fratiglioni, L. Cognitive decline, dietary factors and gut-brain interactions. Mech Ageing Dev. 2015;136–137:5969.
49. Hill, JM, Clement, C, Pogue, AI, Bhattacharjee, S, Zhao, Y, Lukiw, WJ. Pathogenic microbes, the microbiome, and Alzheimer’s disease (AD). Front Aging Neurosci. 2014;6:127.
50. Bhattacharjee, S, Lukiw, WJ. Alzheimer’s disease and the microbiome. Front Cell Neurosci. 2013;7:153.
51. Mayer, EA, Knight, R, Mazmanian, SK, Cryan, JF, Tillisch, K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014;34(46):15490–6.
52. Zapata, HJ, Quagliarello, VJ. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc. 2015;63(4):776–81.
53. Hill, JM, Bhattacharjee, S, Pogue, AI, Lukiw, WJ. The gastrointestinal tract microbiome and potential link to Alzheimer’s disease. Front Neurol. 2014;5:43.
54. Tremlett, H, Bauer, KC, Appel-Cresswell, S, Finlay, BB, Waubant, E. The gut microbiome in human neurological disease: a review. Ann Neurol. 2017;81(3):369–82.
55. Mather, KA, Kwok, JB, Armstrong, N, Sachdev, PS. The role of epigenetics in cognitive ageing. Int J Geriatr Psychiatry. 2014;29(11):1162–71.
56. Akbarian, S, Beeri, MS, Haroutunian, V. Epigenetic determinants of healthy and diseased brain aging and cognition. JAMA Neurol. 2013;70(6):711–8.
57. Ashish, N, Bhatt, P, Toga, AW. Global data sharing in Alzheimer disease research. Alzheimer Dis Assoc Disord. 2016;30(2):160–8.

Keywords

Type Description Title
PDF
Supplementary materials

Chertkow et al. supplementary material
Chertkow et al. supplementary material 1

 PDF (711 KB)
711 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed